EGFR and ovarian carcinoma: Although EGFR is expressed in 90% of certain subtypes of ovarian cancers, this molecule has a response rate of 0–6% in patients with persistent or recurrent disease, preventing it from being a therapeutic target and a potential prognostic biomarker in ovarian cancer12, as it lacks meaningful survival qualities.